Systemic Treatment in Luminal A & B Breast cancers

Breast cancer is classified into several categories according to the different designs.The practical aim is to classify is to describe each individual instance of breast cancerin a way that helps select which treatment approach is anticipated to have the bestchance for a good outcome, with increased efficacy and low toxicity.Receptor status was traditionally considered by reviewing each individual receptor(ER, PR, her2) in turn, but newer approaches look at these together, along with thetumor grade, to categorize breast cancer into several conceptual molecular classes.That has different prognoses and may have different responses to specific therapies.Estrogen receptor (ER)-positive breast cancer is the most prevalent subtype ofinvasive breast cancers. Patients with ER-positive breast cancers have variable clinicaloutcomes and responses to endocrine therapy and chemotherapy. With the advent ofmicroarray-based gene expression profiling, unsupervised analysis methods haveresulted in a classification of ER-positive disease into subtypes with differentoutcomes (ie, luminal A and luminal B); . In this review, we discuss about thesesubtypes and their different treatment.